[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 52
Citations 0
Correction
December 6, 2018

Incorrect Treatment Group in Results and Error in Legend of Figure 2

JAMA Oncol. Published online December 6, 2018. doi:10.1001/jamaoncol.2018.6113

In the article titled “Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial,”1 a single instance of the incorrect treatment group was named in the beginning of the Results, and the overall survival rates for nivolumab and dacarbazine in the caption for part A of Figure 2 were incorrect. In the Results, the sentence has been revised to read, “…in the dacarbazine group, the median age of patients was 66 years (25-87 years)…”, and in the caption for part A of Figure 2, the rates have been revised to read, “For nivolumab, the overall survival rate at 1 year was 71%; 2 years, 58%; and 3 years, 51%. For dacarbazine, the overall survival rate at 1 year was 46%; 2 years, 26%; and 3 years, 22%.” This article has been corrected online.

References
1.
Ascierto  PA, Long  GV, Robert  C,  et al.  Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial  [published online October 25, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.4514Google Scholar
×